PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan
WBA vs. GSK
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

WBA vs. GSK

Last updated Apr 1, 2026

Compare and contrast key facts about Walgreens Boots Alliance, Inc. (WBA) and GlaxoSmithKline plc (GSK).

Performance

WBA vs. GSK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Walgreens Boots Alliance, Inc. (WBA) and GlaxoSmithKline plc (GSK). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

WBA vs. GSK - Yearly Performance Comparison

2026 (YTD)202520242023202220212020201920182017
WBA
Walgreens Boots Alliance, Inc.		0.00%28.40%-61.34%-25.09%-25.06%35.78%-29.38%-10.99%-3.65%-10.51%
GSK
GlaxoSmithKline plc		13.45%51.23%-5.14%9.71%-33.41%26.74%-17.72%29.24%13.79%-2.97%

Fundamentals

EPS

WBA:

-$7.28

GSK:

$2.78

PS Ratio

WBA:

0.07

GSK:

3.54

Total Revenue (TTM)

WBA:

$154.58B

GSK:

$31.95B

Gross Profit (TTM)

WBA:

$26.47B

GSK:

$23.18B

EBITDA (TTM)

WBA:

-$2.92B

GSK:

$11.62B

Returns By Period

WBA

1D
—
1M
—
YTD
—
6M
—
1Y
—
3Y*
—
5Y*
—
10Y*
—

GSK

1D
1.77%
1M
-6.66%
YTD
13.45%
6M
30.03%
1Y
48.15%
3Y*
20.43%
5Y*
8.75%
10Y*
5.74%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Walgreens Boots Alliance, Inc.

GlaxoSmithKline plc

Often compared with WBA:
WBA vs. CVSWBA vs. VZWBA vs. MSWBA vs. DNAWBA vs. IYTWBA vs. SPYWBA vs. WTRG
Often compared with GSK:
GSK vs. AZN.LGSK vs. PFEGSK vs. NVSGSK vs. RHHBYGSK vs. SAN.PAGSK vs. RXRXGSK vs. SHEL

Return for Risk

WBA vs. GSK — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
WBA
GSK
GSK Risk / Return Rank: 8585
Overall Rank
GSK Sharpe Ratio Rank: 8888
Sharpe Ratio Rank
GSK Sortino Ratio Rank: 8484
Sortino Ratio Rank
GSK Omega Ratio Rank: 8181
Omega Ratio Rank
GSK Calmar Ratio Rank: 8888
Calmar Ratio Rank
GSK Martin Ratio Rank: 8585
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

WBA vs. GSK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Walgreens Boots Alliance, Inc. (WBA) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

WBA vs. GSK - Sharpe Ratio Comparison

Loading graphics...

Sharpe Ratios by Period

WBAGSKDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

—

1.70

—

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

—

0.36

—

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

—

0.25

—

Sharpe Ratio (All Time)

Calculated using the full available price history

—

0.33

—

Correlation

The correlation between WBA and GSK is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

WBA vs. GSK - Dividend Comparison

WBA has not paid dividends to shareholders, while GSK's dividend yield for the trailing twelve months is around 3.19%.

TTM20252024202320222021202020192018201720162015
WBA
Walgreens Boots Alliance, Inc.		0.00%0.00%10.72%7.35%5.13%3.62%4.64%3.04%2.46%2.13%1.78%1.64%
GSK
GlaxoSmithKline plc		3.19%3.42%4.60%3.75%5.47%4.99%5.59%4.35%5.65%5.83%6.86%5.93%

Drawdowns

WBA vs. GSK - Drawdown Comparison

Loading graphics...

Drawdown Indicators

WBAGSKDifference

Max Drawdown

Largest peak-to-trough decline

—

-55.70%

—

Max Drawdown (1Y)

Largest decline over 1 year

—

-14.80%

—

Max Drawdown (5Y)

Largest decline over 5 years

—

-50.10%

—

Max Drawdown (10Y)

Largest decline over 10 years

—

-50.10%

—

Current Drawdown

Current decline from peak

—

-9.07%

—

Average Drawdown

Average peak-to-trough decline

—

-18.90%

—

Ulcer Index

Depth and duration of drawdowns from previous peaks

—

6.37%

—

Volatility

WBA vs. GSK - Volatility Comparison

Loading graphics...

Volatility by Period

WBAGSKDifference

Volatility (1M)

Calculated over the trailing 1-month period

—

7.26%

—

Volatility (6M)

Calculated over the trailing 6-month period

—

19.71%

—

Volatility (1Y)

Calculated over the trailing 1-year period

—

28.43%

—

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

—

24.74%

—

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

—

22.72%

—

Financials

WBA vs. GSK - Financials Comparison

This section allows you to compare key financial metrics between Walgreens Boots Alliance, Inc. and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.

Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities

5.00B10.00B15.00B20.00B25.00B30.00B35.00B40.00BAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
38.99B
7.90B
(WBA) Total Revenue
(GSK) Total Revenue
Values in USD except per share items